Hope for hair loss: new pill targets scarring alopecia
NCT ID NCT07508488
First seen Apr 19, 2026 · Last updated Apr 24, 2026 · Updated 2 times
Summary
This study tests a daily pill called deucravacitinib in 20 adults with two types of scarring hair loss (CCCA and FFA). The goal is to see if the drug can reduce inflammation and scarring on the scalp over 48 weeks. Participants take the medication for the entire study period, so it is a disease-control approach, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.